









Markets
/
Stocks
/
nasdaq-gern
/

Geron Corp

GERN

1.320USD

+0.050+3.94%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

841.96MMarket Cap

LossP/E TTM



Geron Corp

1.320

+0.050+3.94%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

82 / 506

Overall Ranking

186 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

3.625

Target Price

+185.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 12818.46% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.99M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 23.02.

Undervalued

The company’s latest PE is -10.21, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 522.02M shares, decreasing 17.38% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 35.49M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 8.32, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 49.04M, representing a year-over-year increase of 5459.64%, while its net profit experienced a year-over-year increase of 75.70%.

Score

Industry at a Glance

Previous score

8.32

Change



Financials

6.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.99

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.45

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -9.82, which is -29.39% below the recent high of -6.93 and -1.81% above the recent low of -10.00.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 7.78, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Geron Corp is 4.00, with a high of 6.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.78

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

3.625

Target Price

+185.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Geron Corp

GERN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 6.10, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 1.45 and the support level at 1.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.10

Change

0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.028

Sell

RSI(14)

47.492

Neutral

STOCH(KDJ)(9,3,3)

30.977

Buy

ATR(14)

0.068

High Vlolatility

CCI(14)

-36.907

Neutral

Williams %R

68.966

Sell

TRIX(12,20)

-0.223

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.276

Buy

MA10

1.312

Buy

MA20

1.369

Sell

MA50

1.325

Sell

MA100

1.378

Sell

MA200

1.957

Sell

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 81.82%, representing a quarter-over-quarter increase of 0.25%. The largest institutional shareholder is The Vanguard, holding a total of 35.49M shares, representing 5.56% of shares outstanding, with 0.63% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

60.38M

+101.20%

BlackRock Institutional Trust Company, N.A.

43.06M

-2.29%

Deep Track Capital LP

38.18M

+851.72%

The Vanguard Group, Inc.

Star Investors

34.02M

+1.82%

Vivo Capital, LLC

27.23M

Vestal Point Capital, LP

22.01M

+100.05%

State Street Global Advisors (US)

23.91M

-11.95%

ClearBridge Investments, LLC

8.69M

Geode Capital Management, L.L.C.

13.57M

+3.24%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.